Cargando…

A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML

The proportion of patients with acute myeloid leukemia (AML) cured is increased by administering high-dose cytarabine (HiDAC). It remains uncertain whether to administer HiDAC as induction or consolidation, and whether ≥1 cycle of HiDAC is required. Our retrospective study of 416 adult AML patients,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schwarer, Anthony P., Butler, Jason, Jackson, Kathryn, Beligaswatte, Ashanka, Martin, Louisa, Kennedy, Glen, Daniela, Zantomio, Lewis, Ian, Hiwase, Devendra, Wight, Joel, He, Simon, Grigg, Andrew, Morris, Kirk, Mollee, Peter, Marlton, Paula
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745967/ https://www.ncbi.nlm.nih.gov/pubmed/31723796 http://dx.doi.org/10.1097/HS9.0000000000000158

Ejemplares similares

PB1838: TOXICITY AND OUTCOME OF HIGH DOSE CYTARABINE (18 G/M2) FOR AML CONSOLIDATION.
por: Lopes, L., et al.
Publicado: (2022)

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML
por: Malani, D, et al.
Publicado: (2017)

Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
por: Gyan, Emmanuel, et al.
Publicado: (2022)

ML-08 Safety and efficacy of consolidation cytarabine for newly-diagnosed primary central nervous system lymphoma
por: Sasaki, Nobuyoshi, et al.
Publicado: (2020)

Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
por: Hanoun, Maher, et al.
Publicado: (2022)

Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia()
por: Bradstock, Kenneth F., et al.
Publicado: (2016)

Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia
por: Liu, Qingguo, et al.
Publicado: (2020)

Meta-Analysis of Randomised Clinical Trials Comparing Idarubicin + Cytarabine with Daunorubicin + Cytarabine as the Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukaemia
por: Wang, Jing, et al.
Publicado: (2013)

Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
por: Raut, Lalit S.
Publicado: (2015)

Standard-Intensity Induction and Intermediate/High-Dose Cytarabine Consolidation Can Improve Survival for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Cohort Study
por: Wang, Li, et al.
Publicado: (2022)

High-dose cytarabine monotherapy is superior to standard-dose cytarabine- based multiagent sequential treatment cycle for consolidation treatment in adult (14-59 years) AML patients according to European Leukemia Net 2022 risk stratification
por: Wang, Xiaoyu, et al.
Publicado: (2023)

AML consolidation therapy: timing matters
por: Reimann, Adrian-Manuel, et al.
Publicado: (2023)

High efficacy of azacitidine combined with homoharringtonine, idarubicin, and cytarabine in newly diagnosed patients with AML: A single arm, phase 2 trial
por: Li, Jun, et al.
Publicado: (2022)

Retrospective Comparison of Fludarabine in Combination With Intermediate-Dose Cytarabine Versus High-Dose Cytarabine As Consolidation Therapies for Acute Myeloid Leukemia
por: Zhang, Wenjun, et al.
Publicado: (2014)

HOXA11 plays critical roles in disease progression and response to cytarabine in AML
por: Fu, Jen-Fen, et al.
Publicado: (2021)

Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens
por: Rassidakis, George Z., et al.
Publicado: (2018)

The role of VDR and BIM in potentiation of cytarabine–induced cell death in human AML blasts
por: Harrison, Jonathan S., et al.
Publicado: (2016)

Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine
por: Tabe, Yoko, et al.
Publicado: (2018)

Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial
por: Jädersten, Martin, et al.
Publicado: (2022)

Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach
por: Pugliese, Giusj Monia, et al.
Publicado: (2023)

P564: HOMOHARRINGTONINE AND CYTARABINE COMBINED WITH VENETOCLAX (HAV) FOR ADULT PATIENTS WITH DE NOVO AML
por: Luo, Xiao-Hua, et al.
Publicado: (2023)

PB2363: R-MPV FOLLOWED BY CONSOLIDATION REDUCED-DOSE WHOLE-BRAIN RADIOTHERAPY AND CYTARABINE IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA: REAL WORLD DATA
por: Amani, Maha EL, et al.
Publicado: (2023)

P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN-LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V-FLAI) IN THE INDUCTION THERAPY OF NON LOW-RISK AML
por: Minetto, Paola, et al.
Publicado: (2023)

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
por: Chen, Evan C, et al.
Publicado: (2018)

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results
por: Cortes, Jorge E., et al.
Publicado: (2018)

Combination of Cladribine and Cytarabine is Effective for Childhood Acute Myeloid Leukemia: Results of the St. Jude AML97 Trial
por: Rubnitz, Jeffrey E., et al.
Publicado: (2009)

Upregulation of microRNA-126-5p is associated with drug resistance to cytarabine and poor prognosis in AML patients
por: SHIBAYAMA, YOSHIHIKO, et al.
Publicado: (2015)

Genome-wide association analysis identifies SNPs predictive of in vitro leukemic cell sensitivity to cytarabine in pediatric AML
por: Bargal, Salma A., et al.
Publicado: (2018)

Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in acute myeloid leukemia (AML)
por: Omsland, Maria, et al.
Publicado: (2016)

IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen
por: Libura, Marta, et al.
Publicado: (2021)

Effect of Granulocyte Colony-Stimulating Factor on the Development of Spermatogenesis in the Adulthood of Juvenile AML Mice Model Treated with Cytarabine
por: Khaleel, Bara’ah, et al.
Publicado: (2023)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
por: Lancet, Jeffrey E., et al.
Publicado: (2018)

Infectious complications after induction chemotherapy with FLAI(E) in newly diagnosed AML, omitting antibacterial prophylaxis
por: Santoni, Adele, et al.
Publicado: (2023)

Diagnostic yield, indications, and outcomes of cranial imaging in AML patients admitted for intensive induction or consolidation chemotherapy: a single-center experience
por: Koschade, Sebastian E., et al.
Publicado: (2023)

Disrupting the LC3 Interaction Region (LIR) Binding of Selective Autophagy Receptors Sensitizes AML Cell Lines to Cytarabine
por: Putyrski, Mateusz, et al.
Publicado: (2020)

Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis
por: Tomic, Barbara, et al.
Publicado: (2022)

Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML
por: Halpern, Anna B., et al.
Publicado: (2023)

Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia
por: Azevedo, M.C., et al.
Publicado: (2014)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
por: Zhang, Baohang, et al.
Publicado: (2023)

A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone
por: Hahn, C N, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6ib6ae1efvg877qvsvg6vlof7p